Search
F-box/WD repeat-containing protein 1A
go.drugbank.com/bio_entities/BE0021224TargetHumansMediates ubiquitination of REST, thereby leading to its proteasomal degradation (PubMed:18354482, PubMed:21258371).
Polypeptides: F-box/WD repeat-containing protein 1AMifamurtide
go.drugbank.com/drugs/DB13615ApprovedInvestigationalAlso called L-MTP-PE, mifamurtide may be a liposomal form of of the active ingredient MTP-PE, which is a synthetic, less pyrogenic, and longer-acting derivative of muramyl dipeptide (MDP). … The overall result of MDP recognition leads to the production of proinflammatory cytokines and promotion of bactericidal and tumoricidal effects [A31745].
Tramadol
go.drugbank.com/drugs/DB00193ApprovedInvestigationalTramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to codeine and morphine. Due to its good tolerability profile and multimodal mechanism of actio...
Mixtures: DUODUET - PT, AUROMYOTRAM-P ® TABLETASCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesAluminum zirconium octachlorohydrex gly
go.drugbank.com/drugs/DB11200ApprovedAluminum zirconium octachlorohydrex gly is complex that consists of aluminum zirconium octachlorohydrate and glycine. It is an active antiperspirant agent , . It diffuses into the sweat pores and prevents perspiration (sweat) from leavin...
Products: Secret Outlast pH Balanced Invisible, Lady Speed Stick Clinical Proof pH activeMomelotinib
go.drugbank.com/drugs/DB11763ApprovedInvestigationalMF includes primary MF (PMF), post-polycythemia vera (PV) MF, and post-essential thrombocythemia (ET) MF. Clinical manifestations of MF include anemia and thrombocytosis.
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesTavapadon
go.drugbank.com/drugs/DB14899ApprovedTavapadon is an oral non-ergot dopamine agonist that acts as a selective partial agonist at the dopamine D1 and D5 receptors. It is used to treat Parkinson's disease in adults. The FDA approved tavapadon in September 2026 for the treatme...
Synonyms: PF-06649751Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesElagolix
go.drugbank.com/drugs/DB11979ApprovedInvestigationalIn particular, estimates suggest that one in ten women of reproductive age is affected by endometriosis and experience debilitating pain symptoms [A35868, A35869, F801]. … Moreover, women who are affected by this condition can suffer for up to six to ten years and visit multiple physicians before receiving a proper diagnosis [A35868, A35869, F801].
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsSelumetinib
go.drugbank.com/drugs/DB11689ApprovedInvestigationalThe novel MEK 1/2 inhibitor, selumetinib, was initially approved solely for the treatment of pediatric patients with Neurofibromatosis type 1 (NF-1) and symptomatic, inoperable plexiform neurofibromas (PN
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesIdelalisib
go.drugbank.com/drugs/DB09054ApprovedInvestigationalMore specifically, idelalisib targets P110δ, the delta isoform of the enzyme phosphatidylinositol-4,5-bisphosphate 3-kinase, also known as PI-3K. … The PI-3Ks are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesLeucine-rich repeat-containing G protein-coupled receptor 5
go.drugbank.com/bio_entities/BE0010835TargetHumansReceptor for R-spondins that potentiates the canonical Wnt signaling pathway and acts as a stem cell marker of the intestinal epithelium and the hair follicle. Upon binding to R-spondins (RSPO1, RSPO2, RSPO3 or RSPO4), associates with ph...
Polypeptides: Leucine-rich repeat-containing G protein-coupled receptor 5